论文部分内容阅读
目的观察米非司酮治疗子宫肌瘤的临床效果。方法选取2013年1~9月收治的子宫肌瘤患者86例,给予米非司酮12.5mg/d,连服3个月。比较治疗前后B型超声监测下的子宫肌瘤体积变化,检查测定性激素:卵泡雌激素(FSH)、黄体生成素(LH)、雌激素(E2)、孕酮(P),及治疗前后血常规、肝肾功能情况。结果治疗后肿瘤体积为(21.5±5.7)cm3较治疗前明显缩小,性激素水平E2、LH、P较治疗前明显下降,差异有统计学意义(P<0.05);血FSH与治疗前比较,差异无统计学意义(P>0.05)。且未见明显不良反应。结论米非司酮在治疗子宫肌瘤中可以缩小肌瘤体积,减轻症状,且无明显不良反应,值得临床推广应用。
Objective To observe the clinical effect of mifepristone in treating uterine fibroids. Methods Totally 86 patients with uterine leiomyoma treated from January to September in 2013 were given 12.5 mg / d of mifepristone for 3 months. The changes of uterine leiomyoma volume before and after B-mode ultrasonography were compared. The levels of FSH, LH, E2, progesterone (P), and blood routine Liver and kidney function. Results After treatment, the volume of tumor was (21.5 ± 5.7) cm3, which was significantly smaller than that before treatment. The levels of sex hormones E2, LH and P were significantly lower than those before treatment (P <0.05) No statistical significance (P> 0.05). And no obvious adverse reactions. Conclusion Mifepristone in the treatment of uterine fibroids can reduce fibroids volume, reduce symptoms, and no significant adverse reactions, it is worth promoting the clinical application.